Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NeuBase Therapeutics stock | $3.92

Learn how to easily invest in NeuBase Therapeutics stock.

NeuBase Therapeutics Inc is a biotechnology business based in the US. NeuBase Therapeutics shares (NBSE) are listed on the NASDAQ and all prices are listed in US Dollars. NeuBase Therapeutics employs 15 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in NeuBase Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NBSE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NeuBase Therapeutics stock price (NASDAQ: NBSE)

Use our graph to track the performance of NBSE stocks over time.

NeuBase Therapeutics shares at a glance

Information last updated 2021-10-17.
Latest market close$3.92
52-week range$3.26 - $12.89
50-day moving average $3.80
200-day moving average $4.63
Wall St. target price$16.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.92

Buy NeuBase Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NeuBase Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NeuBase Therapeutics price performance over time

Historical closes compared with the close of $3.92 from 2021-10-20

1 week (2021-10-14) -3.21%
1 month (2021-09-21) 1.82%
3 months (2021-07-21) -2.49%
6 months (2021-04-21) -34.67%
1 year (2020-10-21) -55.56%
2 years (2019-10-21) -15.88%
3 years (2018-10-19) 1,481.92%
5 years (2016-10-21) 4.53%

NeuBase Therapeutics financials

Gross profit TTM $0
Return on assets TTM -28.5%
Return on equity TTM -48.34%
Profit margin 0%
Book value $1.84
Market capitalisation $128.9 million

TTM: trailing 12 months

Shorting NeuBase Therapeutics shares

There are currently 501,531 NeuBase Therapeutics shares held short by investors – that's known as NeuBase Therapeutics's "short interest". This figure is 5% down from 527,907 last month.

There are a few different ways that this level of interest in shorting NeuBase Therapeutics shares can be evaluated.

NeuBase Therapeutics's "short interest ratio" (SIR)

NeuBase Therapeutics's "short interest ratio" (SIR) is the quantity of NeuBase Therapeutics shares currently shorted divided by the average quantity of NeuBase Therapeutics shares traded daily (recently around 129260.56701031). NeuBase Therapeutics's SIR currently stands at 3.88. In other words for every 100,000 NeuBase Therapeutics shares traded daily on the market, roughly 3880 shares are currently held short.

However NeuBase Therapeutics's short interest can also be evaluated against the total number of NeuBase Therapeutics shares, or, against the total number of tradable NeuBase Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeuBase Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 NeuBase Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0188% of the tradable shares (for every 100,000 tradable NeuBase Therapeutics shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NeuBase Therapeutics.

Find out more about how you can short NeuBase Therapeutics stock.

NeuBase Therapeutics share dividends

We're not expecting NeuBase Therapeutics to pay a dividend over the next 12 months.

Have NeuBase Therapeutics's shares ever split?

NeuBase Therapeutics's shares were split on a 1:20 basis on 3 February 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeuBase Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NeuBase Therapeutics shares which in turn could have impacted NeuBase Therapeutics's share price.

NeuBase Therapeutics share price volatility

Over the last 12 months, NeuBase Therapeutics's shares have ranged in value from as little as $3.26 up to $12.89. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuBase Therapeutics's is -0.1293. This would suggest that NeuBase Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NeuBase Therapeutics has bucked the trend.

NeuBase Therapeutics overview

NeuBase Therapeutics, Inc. , a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. .

Frequently asked questions

What percentage of NeuBase Therapeutics is owned by insiders or institutions?
Currently 8.329% of NeuBase Therapeutics shares are held by insiders and 32.914% by institutions.
How many people work for NeuBase Therapeutics?
Latest data suggests 15 work at NeuBase Therapeutics.
When does the fiscal year end for NeuBase Therapeutics?
NeuBase Therapeutics's fiscal year ends in September.
Where is NeuBase Therapeutics based?
NeuBase Therapeutics's address is: 700 Technology Drive, Pittsburgh, PA, United States, 15219
What is NeuBase Therapeutics's ISIN number?
NeuBase Therapeutics's international securities identification number is: US64132K1025
What is NeuBase Therapeutics's CUSIP number?
NeuBase Therapeutics's Committee on Uniform Securities Identification Procedures number is: 64132K102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site